Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Abnormalities of chromosome (ch)1 have been shown to be significant adverse prognostic factors in multiple myeloma (MM) but they have not yet been systematically studied in patients undergoing autologous hematopoietic cell transplantation (auto-HCT). The aim of this study was to determine whether patients with high-risk MM and ch1 abnormalities (1q gain, 1p deletion, translocations of ch1) constitute a highest risk group compared to a contemporaneous cohort of high-risk MM patients without ch1 abnormalities. 232 patients (169 induction, 63 salvage) with MM and at least one recognized high-risk feature met criteria for inclusion. The presence of a ch1 abnormality (n=15) was highly significant in patients undergoing salvage autologous HCT (n=6) for predicting shorter PFS (p<0.001; HR= 22.93; 95% CI: 4.94- 106.48), and OS (p = 0.0002; HR= 21.22; 95% CI: 1.18-14.98). Median PFS and OS for those with a ch1 abnormality and del 13q (n=7) were 4.76 and 9.43 months, with ch1 abnormality and no del 13q (n=8) were 16.79 and 35.22 months respectively, and for those Without cytogenetic abnormalities, 24.44 and 57.03 months respectively. Based upon the impact of ch1 abnormalities on auto-HCT outcomes in this study, further investigation in larger series is warranted..read more
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi